The PD-1 and PD-L1 inhibitors competitive landscape report delivers important insights into approved as well as ongoing research of 200+ pipeline PD-1 and PD-L1 inhibitor drugs, clinical strategies, ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company’s approach to ...
The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), ...
Morning Overview on MSN
An experimental Alzheimer’s immune therapy cleared its first safety trial with positive results
An experimental antibody designed to briefly block the immune checkpoint PD-L1 in the brain has cleared its first human ...
Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the tumor site for ...
A new review article outlines the latest research and results into programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors for the treatment of myelodysplastic syndromes (MDS) ...
Personalized recommendations for patients with non–small cell lung cancer with squamous histology could benefit from research on treatment choice and biomarkers, noted Blythe Adamson, PhD, MPH, ...
The Practical Application of Emerging Technologies Influencing the Diagnosis and Care of Patients With Primary Brain Tumors Comprehensive next-generation sequencing platforms provide tumor genomic ...
MedPage Today on MSN
Biomarkers for Esophageal Cancer Continue to Evolve
Recently validated markers have helped improve treatment but more are needed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results